Health
Azelastine antihistamine inhibits SARS-CoV-2 infection in nasal tissue in vitro – News-Medical.Net
In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.
In a study published on the bioRxiv* preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.
The COVID-19 pandemic has caused a pressing need for the rapid development of both preventive and therapeutic approaches to fight the virus. Given the urgency, going through the traditional drug discovery and development pathway is not feasible…
-
Business16 hours agoCould a small investor today match the historic returns of Warren Buffett?
-
Business8 hours agoWhat’s Macquarie’s price target on Mineral Resources shares?
-
General15 hours agoPope Leo condemns wealthy living in a bubble of luxury
-
Noosa News14 hours agoQueensland government to set up $400m energy investment fund